Vanguard Personalized Indexing Management LLC Has $2.07 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Vanguard Personalized Indexing Management LLC grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 22.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,503 shares of the biotechnology company’s stock after purchasing an additional 1,187 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in United Therapeutics were worth $2,069,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Renaissance Technologies LLC increased its position in shares of United Therapeutics by 1.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after purchasing an additional 22,978 shares during the last quarter. LSV Asset Management increased its position in shares of United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after purchasing an additional 436,851 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of United Therapeutics by 4.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock worth $186,656,000 after purchasing an additional 22,683 shares during the last quarter. Norges Bank acquired a new position in shares of United Therapeutics during the 4th quarter worth approximately $100,519,000. Finally, Swedbank AB acquired a new position in shares of United Therapeutics during the 1st quarter worth approximately $97,316,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Performance

UTHR opened at $353.00 on Friday. The business has a fifty day simple moving average of $338.55 and a 200 day simple moving average of $290.39. The company has a market capitalization of $15.70 billion, a PE ratio of 16.69, a price-to-earnings-growth ratio of 1.25 and a beta of 0.57. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $366.08. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). The firm had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same quarter last year, the firm earned $5.24 earnings per share. Research analysts expect that United Therapeutics Co. will post 24.86 EPS for the current year.

Insider Activity

In other news, CFO James Edgemond sold 7,802 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the completion of the sale, the chief financial officer now directly owns 3,210 shares in the company, valued at approximately $1,108,766.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, COO Michael Benkowitz sold 25,000 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $833,350.26. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO James Edgemond sold 7,802 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82. Following the sale, the chief financial officer now owns 3,210 shares of the company’s stock, valued at $1,108,766.10. The disclosure for this sale can be found here. In the last three months, insiders sold 110,922 shares of company stock worth $36,541,398. 12.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on UTHR. Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $310.00 to $321.00 in a report on Thursday, July 11th. Oppenheimer boosted their target price on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a report on Wednesday, August 28th. LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. Wells Fargo & Company boosted their target price on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. Finally, UBS Group boosted their target price on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $350.36.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.